A focus on active pharmaceutical ingredients, data integrity and sterility assurance was evident in inspection reports, an untitled letter and a warning letter that the US Food and Drug Administration recently published, as well as a recent EU GMP noncompliance report.
The agency disclosed a drug GMP warning letter 31 October that focused on control of porcine ingredients for prescription hypothyroidism treatments, unusual in that of late, most drug GMP
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?